The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
Conducted by patient services specialist Greenphire, the survey checks in with contract research organizations and shows how they are approaching obstacles.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
The protease inhibitor PF-07321332 (co-administered with ritonavir) is designed for patients exposed to (or showing the first signs of) the COVID-19 virus.
As COVID-19 and its variants continue their attack, the agency maintains its position of overseer and giver of advice on various treatments and vaccines.
The cancer-centric pharma firm will collaborate with the Philadelphia-based cancer center to pinpoint new indications and biomarkers for its drug candidate.
SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.
Biocair has expanded its pharmaceutical and clinical trial logistics operations with new location in California, near Los Angeles International Airport.
A logistics leader from the CRO offers advice on navigating borders, cultures, regulatory issues and other important considerations on worldwide studies.
A leader from the global clinical research logistics company shares how to weigh the complex aspects of a decentralized trial and craft intelligent strategy.
According to a leader from the health engagement solutions firm, intelligent use of technology tools can add patient-centricity and realism to a study.
A report from the industry event’s organizers indicates American companies have an edge on drug delivery innovation but lag in operational sustainability.
Swift Skin and Wound is a digital imaging technology designed to support decentralized clinical trials conducted to evaluate skin and wound treatments.
Two experts from the contract research organization offer advice on planning and executing clinical studies with the unique needs of such patients in mind.
Stakeholders in the Rare Disease Cures Accelerator-Data and Analytics Platform initiative are partnering in hopes of bringing treatments to patients faster.
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
This month’s roundup of new technology, equipment, and industry partnerships includes news from IBM, IQVIA, Mediata, Labcorp, and other notable companies.
A physician assistant from Hawthorne Effect shares how she and other trained health professionals contribute their knowledge and talents to in-home studies.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The pharma tech firm has forged a four-year partnership with the foundation to develop antivirals for COVID-19 and other viruses with pandemic potential.
The advocacy organization's PIE4CNS initiative is aimed at targeting and reducing gaps in diagnosis, research, and trials for rare neurological conditions.
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The two companies are collaborating on development of Myfembree, a combination therapy to treat the painful condition affecting millions of women worldwide.
A leader from ACG Engineering shares insight on how ‘smart’ drug manufacturing, accelerated by COVID-19, can best be put to work now and in months to come.
The US agency continues to oversee vaccine and drug development, and to share information and advice for life-sciences professionals and civilians alike.
The digital therapeutics firm's Neuroglee Connect remote care platform and virtual clinic is for patients with mild cognitive impairment, including Alzheimer’s.
Nucala, a monoclonal antibody indicated for patients with chronic rhinosinusitis with nasal polyps, has been approved by the Food and Drug Administration.
A leader from the trial tech firm discusses the pandemic’s impact on studies, and how decentralized technology will be vital in helping industry recovery.
Two leaders from the decentralized trial solutions provider discuss the complex pieces of a global clinical study and how to work to fit them all together.
A representative from Cmed Technology explains how taking stock of existing tech and adding the right new tools can help when switching to virtual clinical studies.
According to an Oracle Health Sciences leader, companies looking to take on decentralized trials should keep a few things in mind before taking the plunge.
The clinical-stage biotech firm and a number of high-profile partners have collaborated on biomarker technology to deliver a more accurate, less invasive option.
A leader from the home trial services provder says patients’ increasing awareness of clinical research has how trial teams should consider their approach.
The trial tech firm says analysis of trials in low- and middle-income regions reveals that innovative statistical methods could make a huge difference.
The decentralized trial tech firm will work with Applied VR on five studies testing the viability of virtual-reality therapy in treating pain patients.
This month’s news on new hires, board launches, acquisitions, and other important news includes items on Pfizer, Javara, Clinical Ink, and other companies.
Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection. A Phase...
According to patient-matching specialist TrialJectory, 90% of cancer patients know the vitality of genetic testing but more than half are not being tested.
The #BlackDataMatters movement aims to improve outcomes for Black women living with breast cancer by increasing their presence in vital clinical research.
Cota has released a survey revealing about two-thirds of cancer patients and their families are unsatisfied at the speed of cancer treatment development.
A leader from the rare and infectious disease treatment specialist talks about ongoing research into a potential treatment for mild-to-moderate COVID-19.
FarmaTrust is helping assemble a collective of public and private firms working on solutions for smart manufacturing and creating medicines of the future.
Merck (known as MSD outside the US and Canada) will partner with the data insights firm on solutions that progress real-world research and innovations.
A study conducted by trial tech firms Curedatis and Climedo Health reveals what trial professionals view as challenges and opportunities in digitalization.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.